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Vinculin, an essential adhesion scaffolding protein, physically links membrane bound 
integrin and cadherin receptors to filamentous actin. Cells that fail to express vinculin or possess 
dysfunctional vinculin exhibit rounded morphology, enhanced motility, and resistance to 
apoptosis and anoikis.6 Therefore, vinculin is classified as a tumor suppressor protein in which 
mutations have serious consequences in cancer. A possible ‘hotspot’ region—an encoded region 
of a protein that is highly inclined to mutate and phenotypically manifest—has been identified at 
in the tail-domain of vinculin at residue R925. At this residue, a specific histidine mutation has 
been linked to several types of cancer. The purpose of this study was to examine the possibility 
of residue R925 as a hotspot region and test whether the R925H mutation in vinculin enhances 
motility properties in a model cell line. To examine the status of R925 as a hotspot region, we 
mined several databases to link certain prevalent mutations in vinculin to different types of 
cancer. R925H was the most prominent mutation in vinculin that was present in 5 types of 
cancer, confirming R925 as a hotspot region. In order to assess whether R925H affected the 
motility of mouse embryonic fibroblasts (MEFs), actin binding and bundling activity of mutant 
vinculin was compared to that of wild-type vinculin. We found that R925H mutant vinculin had 
lower actin bundling ability. To evaluate the changes in motility patterns caused by the 
introduction of R925H, we conducted random motility assays to measure the two-dimensional 
migration of MEFs on micro-fabricated and microfluidic devices. Mutant MEFs on hydrogels 
displayed significant differences in motility compared to wild-type cells—particularly in total 
accumulated distance, persistence and velocity. However, further investigation is required to 
interpret these findings. The insight on the effects of the R925H mutation on cell motility will 
serve as one of the first steps to unravel the complexities of vinculin’s potential role in several 




Cytoskeletal proteins have an active role in maintaining cell shape, structure, signaling 
and mechanical transduction.1,2 Furthermore, these proteins are fundamental in remodeling the 
cell in response to environmental stresses.3 Cytoskeletal remodeling is necessary for a myriad of 
cellular processes such as cell division, morphology, motility and generation of cellular 
responses to external mechanical cues.2,3  
Vinculin is an essential, ubiquitous, and highly conserved scaffolding protein that is 
involved in anchoring actin to the cell membrane in cell-cell and cell-matrix junctions.1,4 It is a 
(~120 kDa) multi-domain protein composed of a large (~90 kD) “head” domain and a smaller 
(~21 kD) “tail” domain, connected by a proline-rich flexible linker loop (Figure 1).4 The head 
and tail interact in an auto-inhibitory fashion that prevents vinculin’s scaffold function.4 The 
autoinhibitory interactions between these domains are released upon ligand binding and/or post-
translational modification.4 This allows vinculin to interact with various proteins, including 
actin.4 Specifically, the head domain of vinculin interacts with cytoskeletal proteins talin, a-
catenin, and a-actinin—these interact with integrins and cadherins based junctions, 
respectively.1,4 The tail domain binds and bundles actin into large filaments, connecting the cell’s 
cytoskeleton to the extracellular matrix (ECM).1 Structurally, the vinculin tail domain is 
composed of five alpha helical bundles, and they interact with paxillin, raver1, and F-actin.1,4 
The tail domain also binds with cell membrane acidic phospholipids, particularly 
phosphoinositide 4,5-phosphate (PIP2).1, 4, 5   
Vinculin is localized in cellular adhesions such as focal adhesions and adherens 
junctions.4 Focal adhesions form mechanical links between actin bundles within a cell and the 
ECM. Specifically, these adhesions facilitate interactions involving transmembrane integrins—
mechanical proteins that attach the cell cytoskeleton to the ECM.4 Adherens junctions are 
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involved in cell-cell adhesion. They occur at cell junctions whose cytoplasmic face is linked to 
the actin cytoskeleton.4 At these adhesion sites, vinculin regulates responses to tension forces by 
mediating the link between transmembrane receptors and actin cytoskeleton.1,4 Here, vinculin 
physically links membrane bound integrin and cadherin receptors to filamentous actin.1 Vinculin 
is recruited to focal adhesions to regulate cell shape, motility and mechanotransduction.4 Some 
of vinculin’s roles include the stabilization of adhesions to actin in response to force, the 
regulation of adhesions at the leading edge of migrating mesenchymal cells, and the mediation of 
transmission of traction forces.5 These roles are achieved through vinculin’s interactions with 
over 19 binding partners.4 
Through its active role in cellular adhesion, vinculin is highly involved in the motility of 
cells. Cell motility plays an important role at several steps in cancer metastasis, or the spread of 
cancer cells from the primary tumor to other places in the body.7 Specific stages of metastasis 
include escaping the primary tumor, migration to other areas in the body, and movement into 
distant organs.7  However, cell lines lacking vinculin have demonstrated phenotypes that share 
striking similarities with typical cancer cells.6,7 These phenotypes include a rounded 
morphology, enhanced cell motility, and resistance to apoptosis and anoikis.6 Additionally, 
observations that link the loss of function of vinculin, either through deregulation or mutation, to 
several types of cancers signify the involvement of vinculin in cancer.7,8 Consequently, vinculin 
is classified as a tumor suppressor protein.  
A missense histidine mutation in the tail domain of vinculin, in a region important for 
actin bundling and reorganization and lipid binding, was of particular interest to us. This 
mutation occurs at the residue of R925 where arginine is mutated to histidine (Figure 1).4 We 
examined the possibility of R925 as a ‘hotspot’ region—an encoded region of a protein that is 
highly inclined to mutate and phenotypically manifest.7 Further, we hypothesized that fibroblast 
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cells expressing R925H mutant vinculin would demonstrate differences in cell motility. 
Specifically, we sought to examine whether the R925H mutation would render vinculin to 
malfunction, which would lead to cancer-like cell morphologies and motility. We postulated that 
mutant fibroblast cells would exhibit higher velocity, lower persistence, and greater accumulated 
distance. Fibroblasts with dysfunctional vinculin or those that lack vinculin entirely have 
demonstrated these traits on glass.6,11,12  
To confirm that the R925 residue is indeed a hotspot region, we conducted a data-mining 
procedure. Several online cancer genomics databases, such as cBIO portal, COSMIC, and 
intOGen, were utilized to acquire a collection of vinculin mutations linked to cancer 
(Supplemental Figure 1). Amongst the 33 mutations found across these databases, one of the 
most prominent was the R925H mutation in vinculin (Figure 1, Supplemental Figure 1). Linked 
to a total of 12 cases of cancer patients—the highest number of cases reported for a single 
mutation—this missense mutation is involved in esophageal, uterine, lung, cervical and stomach 
cancers (Figure 1, Supplemental Figure 1). Since the R925H was unique, this mutation became 
































Type of Cancer Type of Mutation 
Position on 
Vinculin 
cBio Portal 7 Esophageal, Uterine, Lung, Cervical Missense R925H 
cBio Portal 3 Stomach, Cutaneous Missense R945W/R945L 
cBio Portal 3 Cutaneous, Thyroid, Colorectal Missense R976L/R976Q 
GDC 5 Esophagus, Stomach, Uterus, Cervix, Lung Missense R925H 
Figure 1. The R925 residue is a hotspot region in the vinculin tail domain and the R925H 
mutation is linked to 5 types of cancer. (A) The helical structure of vinculin tail domain is depicted 
by the turquoise color. The red area highlights the R925 residue where the histidine mutation 
occurs. This mutation lies in helix 2 of the tail domain. (B) In the cBIO Portal, the R925H mutation 
is implicated in 7 cases of cancer patients. In the data mining worksheet, this mutation was 
implicated in a total of 12 cases (adapted from cBIO Portal). This figure correlates to Supplemental 
Figure 1. (C) This table demonstrates the mutations in the vinculin tail domain that are linked to the 
highest numbers of cases of cancer (as seen in 1B). The table also lists the types of cancer the 
mutations are linked to. This table was compiled from Genomic Data Commons Data Portal (GDC) 
and cBIO Portal. This table is a truncated version of the data-mining worksheet, see Supplemental 





























In order to understand whether the mutation affects the motility of cells, first we decided 
to investigate if R925H mutant vinculin would demonstrate different actin binding and bundling 
activity as compared to optimally functioning, wild-type vinculin. Actin binding and bundling 
activity is an essential aspect of cell motility, and in turn mechanotransduction. 1,4 High-speed 
actin co-sedimentation assays were performed in order to measure the actin binding capabilities 
of mutant vinculin, wild-type vinculin, and wild-type metavinculin. We conducted low-speed 
actin co-sedimentation assays to evaluate the actin bundling capabilities of these three proteins as 
well. Metavinculin is a splice variant of vinculin that is co-expressed with vinculin.1 This protein 
contains a 68-residue insertion in the vinculin tail domain that confers lower bundling activities 
than vinculin.1,4 Having characterized the binding and bundling properties of metavinculin in 
depth, we included it in the characterization of actin binding and bundling activity as a control to 
ensure that the protein purification and actin co-sedimentation assays were being performed 
correctly.  
Random migration assays were implemented to study the differences in motility caused 
by R925H mutant vinculin. Our experimental design was focused on elucidating the motility of 
live cells by employing micro-fabrication techniques—particularly, studying fibroblast cells in 
both liquid media on glass and durotaxis using hydrogels. Durotaxis is a form of cellular 
migration in which cells are guided by stiffness gradients or cues.12 Studying durotaxis on 
hydrogels is beneficial because directional migration across the stiffness gradient in a hydrogel 
increases mechanic force stimulation on cells. Any mechanical stimulus placed onto cells causes 
talin to bind to the head domain of vinculin and F-actin to bind to the tail domain. Vinculin then 
mediates the transmission of traction forces to the rest of the focal adhesion.1,4 Through the 
function of many proteins, such as integrin, focal adhesions form mechanical links between 
intracellular actin bundles and the extracellular environment.4 Cell membranes then stiffen in 
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response. The greater mechanical stimulus placed on cells by the stiffness gradient of a hydrogel 
causes the cell membrane to further stiffen. Increased stiffness in cell membranes are 
characteristic of tumor cells. 2,6 Stiffness properties of hydrogels can be tuned to better mimic 
physiological conditions, allowing us to more accurately observe the motility of transformed 
cells.6 We used mid-stiffness hydrogels to provide a mechanical stimulus that reasonably 
approximates the in vivo environment of cancer cells. 6 These physiological conditions are not 
taken into account when studying motility on glass.  
Wild-type vinculin and R925H mutant vinculin were both stably expressed in a mouse 
embryonic fibroblast (MEF) cell line. The exogenous expression of mutant vinculin in MEFs 
was equivalent to the endogenous high expression levels of wild-type vinculin in MEFs. MEFs 
were studied on both glass and mid-stiffness hydrogels. Using MEFs facilitated a clear 
comparison between the motility results of null, wild-type and mutated cells. We chose this 
particular cell model system because vinculin knockout MEFs have been well characterized. 6,9,11 
Specifically, we have previously studied the morphology, cell migration and 
mechanotransduction in vinculin knock out MEFs.6 After conducting the random migration 
assays and manually tracking each cell, we focused on the specific migration parameters of 
velocity, accumulated distance and persistence. Velocity of the cell is defined as the speed of a 
cell’s movement. Persistence is the tendency of a cell to move in one particular direction. The 
accumulated distance is the total amount of distance the cells travel. These properties are thought 
to be distinctive in cancer cells, which are known to spread uncontrollably across the body, with 
higher velocity, lower persistence and greater accumulated distance.6,7,10,12 
This research project begins to unravel the complexities of vinculin’s role in cancer 
initiation or maintenance, and assesses whether the R925H mutation promotes cancerous 
properties in cells. In addition to determining whether this mutation occurs in a hotspot region, 
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we were interested in investigating the differences in motility that the vinculin R925H mutation 
induces. We utilized data-mining procedures, actin co-sedimentation assays and random 
migration assays to further this investigation. Though R925 was confirmed to be a hotspot region 
and R925H was found to affect the actin bundling activity of vinculin, only mutant MEFs studied 





Cell Culture, DNA Constructs and Generation of Stable Cell Lines: 
         WT MEFs and vinculin null MEFs were generously supplied by Dr. Brent Hoffman of 
Duke University. All the cells were cultured in Dulbecco’s modified Eagle’s medium, DMEM 
(Invitrogen). The cells were supplemented with 10% fetal bovine serum (Sigma) and penicillin-
streptomycin solution (Sigma). The cell cultures were grown with 5% CO2 in a 37°C incubator.6 
         Dr. Mohammed Ashhar Khan of the Campbell Lab at UNC Chapel Hill generated both 
wild type and R925H mutant vinculin, which were stably expressed in MEFs. The full-length 
human vinculin construct (1-1066) was subcloned into the pBabe-puro vector. The constructs 
were inserted using NgoMIV and SnaBI restriction sites. The pBabe vector was first co-
transfected into HEK 293T packaging cell line with pCL-10A1 (15 mg) packaging DNA. Then 
the media was collected containing the retroviruses. This pBabe retroviral system was utilized to 
generate stable cell lines.6 After 48 hours, the viruses were harvested and then used to infect the 
vinculin null MEFs with polybrene (8 mg/mL) for 24-48 hours. Cells expressing vinculin were 
selected with puromycin (7.5 mg/mL). The cells were then kept under selection pressure (5 
mg/mL puromycin) for about 3 weeks, and sorted for expression by flow cytometry 
(Supplemental Figure 2). Vinculin expression levels were later confirmed by a Western blot, 
demonstrating that exogenous expression of mutant vinculin in MEFs is equivalent to the 
endogenous high expression levels of wild-type vinculin in MEFs.6 These cells were grown in 
the same fashion as the null and wild-type MEFs.  
Once cell cultures reached 70-80% confluence, they were passaged. Trypsin and DMEM 
media were placed in a warm bath for 10 minutes. In the laminar hood, an aspirator was used to 
take up media from original plated cells. Each plate was washed with 5 mL of phosphate-
buffered saline (PBS, 1M) and then 2 mL trypsin was added to each plate—this lifted the cells 
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that were adhered to the surface of the plate. These plates were placed in the incubator for 5 
minutes. To avoid further cleavage, 2 mL media was added to each plate to neutralize the 
trypsin. The new plates were labeled and placed in the laminar hood. We added 9 mL of media to 
each plate. Then 1 mL of solution from the original plate was added to these new plates, creating 
a 1:10 ratio of the number of cells in the new plate to those in the original plate. These new 
plates were incubated for two days. 
Protein Expression and Purification:  
 Dr. Mohammad Ashhar Khan performed protein expression and purification. The 
vinculin tail domain (Vt, residues 879-1066 of the chicken sequence) was cloned into the 
pOlinkH vector. Metavinculin tail (MVt, residues 879-1134 of the chicken sequence) was cloned 
into 2HR-T vector. Vt R925H (Vt sequence with the R925H missense mutation) was prepared 
using appropriate primers (EtonBiosciences, Durham, NC) and the Q5 site-directed mutagenesis 
kit (NEB Inc, MA). They were verified by DNA sequencing (EtonBiosciences, Durham, NC). 
All vectors were transformed into Escherichia coli strain BL21(DE3) and grown at 37 °C and an 
optical density of 0.6–0.8 (600 nm). 13  
 Protein expression was initiated by the addition of isopropyl-D-1-thiogalactopyranoside. 
The cells were grown at 18 overnight and harvested by centrifugation (4.5k rpm, 30 min). Cell 
pellets from this were suspended in lysis buffer and then lysed by sonication. Soluble fractions, 
containing the proteins, were separated from particulate fractions by centrifugation (15k rpm, 45 
min). Proteins were purified by affinity separation using Ni-NTA-agarose beads (Qiagen). Wash 
buffer was run through the column before eluting target proteins using an elution buffer. For His-
tag removal, the eluted volume was dialyzed into TEV cleavage buffer overnight at 4 °C. All 
proteins were collected by running the dialyzed/cleaved volumes over Ni-NTA-agarose beads. 
Size exclusion chromatography by S100 column (GE, Pittsburg, PA) in gel filtration buffer to 
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obtain the highest purity. Protein stocks were stored at −80 °C.13 For exact chemical 
concentrations and buffer formulas, refer to Table 1 (below).  
Table 1. Chemical concentrations and buffer formulas used in protein 
expression/purification. 13  
 
Buffer/ Chemical Name Formula 
Isopropyl-D-1-thiogalactopyranoside for Vt 0.5 mM  
Isopropyl-D-1-thiogalactopyranoside for 
MVt/MVtp 
1 mM  
Lysis buffer for Vt 20 mM Tris, 150 mM NaCl, 5 mM imidazole, 2 
mM β-mercaptoethanol, pH 7.5  
Lysis buffer for MVt 50 mM Tris, 200 mM NaCl, 10 mM imidazole, 2 
mM β-mercaptoethanol, pH 8.0 
Wash buffer for Vt 20 mM Tris, 150 mM NaCl, 60 mM imidazole, 2 
mM β-mercaptoethanol, pH 7.5 for Vt  
Wash buffer for MVt 50 mM Tris, 200 mM NaCl, 25 mM imidazole, 2 
mM β-mercaptoethanol, pH 8.0 for MVt/MVtp 
Elution buffer for Vt 20 mM Tris, 150 mM NaCl, 500 mM imidazole, 2 
mM β-mercaptoethanol, pH 7.5  
Elution buffer for MVt 50 mM Tris, 200 mM NaCl, 250 mM imidazole, 2 
mM β-mercaptoethanol, pH 8.0  
TEV cleavage buffer for Vt 20 mM Tris, 150 mM NaCl, 50 mM imidazole, 2 
mM β-mercaptoethanol, pH 7.5  
TEV cleavage buffer for MVt 50 mM Tris, 200 mM NaCl, 20 mM imidazole, 2 
mM β-mercaptoethanol, pH 8.0 
Gel filtration buffer 10 mM Tris, 200 mM KCl, 10 mM imidazole, 2.5 
mM MgCl2, 1 mM EGTA, 2 mM DTT, pH 7.5 
 
Actin Co-sedimentation Assays:  
Dr. Mohammad Ashhar Khan conducted actin co-sedimentation assays with the purified 
protein obtained from protein expression and purification procedure. High speed co-
sedimentation (150,000 RCF for 60 min at 23 °C) was conducted for the actin binding assay. 
Low speed-cosedimentation (12,000 RCF for 15 min at room temperature) was conducted for the 
actin bundling assay.  For both binding and bundling assays, the supernatant and pellet were 
separated and resuspended to equal volumes. Volumes were analyzed by 15% SDS-PAGE. 
Actin-binding properties were calculated by determining the fractions of proteins present in 
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pellets. Actin-bundling properties were calculating by determining the fractions of actin present 
in the pellets. Through ImageJ, densitometry analysis was performed to obtain results.  
Hydrogel Preparation and Activation: 
Two trials in this study utilized medium stiffness photopolymerizable hydrogels, created 
by Reem Hakeem of the Bear lab at UNC Chapel Hill. These gels were made from a 12% 
acrylamide and 0.6% bis-acrylamide mixture containing the photoactivatable crosslinker lithium 
phenyl-2,4,6-trimethyl-benzoylphosphinate (LAP). Gel polymerization was controlled with a 
Thor Lab 365 nm UV LED oven, in which a 15 mL drop of the hydrogel mixture was 
illuminated with a 0.35% LAP for 2 minutes and 15 seconds. A medium stiffness gel (~25 kPa 
elasticity/stiffness) was prepared by covering a slide coated in polymerizable gel mixture with a 
3D printed opaque mask and then revealing the mask at controlled, slow pace using a syringe 
pump. The gels were coated with Fibronectin (10 mg/mL) via sulfo-SANPAH—a chemical 
cross-linker (25 mg/mL)—under a UV lamp for 30 mins. The resulting hydrogels were 100 
microns thick and were refrigerated.  
Random Cell Migration Assay: 
On Glass: Glass-bottomed culture dishes (MatTek Corp) were coated with 10 μg/ml 
fibronectin (FN) at 37˚C for 1 hour. 5-15 mL of the cell culture was added to 2 mL of DMEM in 
a plate using a micropipette. This was done for each group of cells. Then all the plates were 
placed in the incubator for 2 hours. The metal caps needed to cover each of the samples were 
sprayed with 70% ethanol and dried in the laminar hood prior to use. They were then placed on 
each of the samples and labeled. After putting them in place holders in the VivaView machine, 
the cells were allowed to settle for 30 minutes. Then the cell positions were picked. To better 
represent the entire population of cells, cells of different sizes, locations, and morphologies were 
chosen for each group of cells. In one run, 24 different cells were studied per cell group. Cells 
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were imaged at 37˚C with 5% CO2 with a 20x objective on an Olympus VivaView FL 
microscope (Hooker Imaging Core at UNC) at 10-minute intervals over 20 hours. 
On Hydrogels: The exact procedure described above was followed with the exception of 
using hydrogels in the place of the glass-bottomed culture dishes. 
Analysis: The manual tracking plug-in within ImageJ was used to track each cell’s 
migration. Cells were tracked until they moved out of the frame or divided. The chemotaxis tool 
on ImageJ was utilized to collect information regarding the velocity, persistence and 
accumulated distance of each cell. The data collected was analyzed with a multiple-comparisons 


































Figure 2. R925H mutant vinculin had lower actin bundling ability. This data was generated 
and analyzed by Dr. Mohammad Ashhar Khan. (A) SDS-PAGE analysis of high-speed actin co-
sedimentation assays completed with wild-type vinculin, R925H mutant vinculin and wild-type 
metavinculin (S = supernatant, P = pelleted). Arrows indicate lanes representing the amount of 
vinculin/metavinculin pelleted. (B) Quantification of vinculin or metavinculin fractions in pellets 
represent the actin binding capabilities of wild-type vinculin, R925H mutant vinculin and 
metavinculin. Error bars represent standard deviation. (C) SDS-PAGE analysis of low-speed 
actin co-sedimentation assays completed with wild-type vinculin, R925H mutant vinculin and 
wild-type metavinculin (S = supernatant, P = pelleted). Arrows indicate lanes representing the 
amount of actin pelleted. (D) Quantification of actin fractions present in pellets represent the 
actin bundling capabilities of wild-type vinculin, R925H mutant vinculin and metavinculin. Error 
bars represent standard deviation. Two-sided t-test indicated by non-significant (n.s.), p < 0.05 
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Figure 3. Elongated focal adhesions and rounded cell morphology observed in R925H mutant 
MEFs, which express the same levels of vinculin as wild-type MEFs. (A) This western blot 
shows the exogenous expression level of vinculin and R925H vinculin on a vinculin null MEF 
background. Both expression levels are equivalent to endogenous vinculin expression in WT 
MEFs. (B) Representative fluorescence microscopy images are of the three cell types studied in 
this experiment. Endogenous vinculin was tagged with mEmerald fluorophore in order to 
visualize vinculin expression in both mutant R925H MEFs and wild-type MEFs. Vinculin null 
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Figure 4. R925H mutant MEFs had a higher average velocity on mid-stiffness as compared to 
wild-type MEFs. (A)Representative cell tracks plotted for n>20 cells each for wild-type MEFs, 
vinculin null MEFs, and R925H mutant MEFs on both mid-stiffness hydrogels and glass. 
Migratory plots were generated using ImageJ. (B) In the box and whisker plots, the ends of the 
box represent upper and lower quartiles (outer 25% velocity values). The box spans the 
interquartile range (middle 50% velocity values). The horizontal line inside of the box denotes 
median velocity value. Average velocity is denoted by the X in the box and its value is right 
above it. This plot shows the velocity of cells on a mid-stiffness hydrogel. A total of 125 R925H 
mutant MEFs, 184 wild-type MEFs and 104 vinculin null cells were analyzed. (C) Box and 
whisker plots demonstrate the velocity of cells on glass. A total of 85 R925H mutant MEFs, 44 
wild-type MEFs and 49 vinculin null cells were analyzed. All significant differences with respect 
to wild-type MEFs in (B) and (C) calculated with multiple-comparisons ANOVA tests (95% CI) 























































Figure 5. R925H mutant MEFs had a lower average persistence on mid-stiffness hydrogel as 
compared to wild-type MEFs. Box and whisker plots can be interpreted in the same fashion as 
Figure 4. (A) Box and whisker plots demonstrate the persistence of cells on a mid-stiffness 
hydrogel. A total of 125 R925H mutant MEFs, 184 wild-type MEFs and 104 vinculin null cells 
were analyzed. (B) Box and whisker plots demonstrate the persistence of cells on glass. A total 
of 85 R925H mutant MEFs, 44 wild-type MEFs and 49 vinculin null cells were analyzed. All 
significant differences with respect to wild-type MEFs in (A) and (B) calculated with multiple-
comparisons ANOVA tests (95% CI) indicated by non-significant (n.s.), p < 0.05 (*), p < 0.01 






































Figure 6. R925H mutant MEFs had a higher average accumulated distance on mid- 
stiffness hydrogel as compared to wild-type MEFs. Box and whisker plots can be interpreted in 
the same fashion as Figure 4. (A) Box and whisker plots demonstrate the accumulated distance 
of cells on a mid-stiffness hydrogel. A total of 125 R925H mutant MEFs, 184 wild-type MEFs 
and 104 vinculin null cells were analyzed. (B) Box and whisker plots demonstrate the 
accumulated distance of cells on glass. A total of 85 R925H mutant MEFs, 44 wild-type MEFs 
and 49 vinculin null cells were analyzed. All significant differences with respect to wild-type 
MEFs in (A) and (B) calculated with multiple-comparisons ANOVA tests (95% CI) indicated by 










The R925 residue is a hotspot region in the vinculin tail domain and the R925H mutation is 
linked to 5 types of cancer.  
Vinculin is a scaffolding protein that is localized to focal adhesions, and plays a central 
role in regulating cell shape, motility and mechanotransduction—properties that are evidently 
influenced by cancer.4 Therefore, mutations in vinculin are suspected to induce cancer-like 
motility.7 The R925H mutation in the tail domain of vinculin was of interest to us. The first step 
of this research project was to confirm whether the R925 residue was a hotspot region. In order 
to do this, we conducted a data-mining procedure to find the links between cancer and mutations 
in regions encoding the vinculin protein. We probed cancer genomics databases such as cBIO 
portal, COSMIC, and intOGen. In cBIO portal, 7 cases of cancer—specifically, patients with 
esophageal, uterine, lung, cervical and stomach cancers—were reported to be linked to the 
R925H mutation in vinculin (Figure 1). This was the highest number of cancer cases associated 
with a single missense mutation in the database (Figure 1). After consulting other databases, a 
total of 33 mutations in vinculin were connected to cases of different types of cancer 
(Supplemental Figure 1). R925H was implicated in a total of 12 cases of cancer. Again, this was 
the highest number of cases associated with a single missense mutation. Relative to other 
residues in vinculin, these data demonstrated that the R925 residue had a higher inclination to 
mutate and manifest in cancer. This confirmed the R925 residue as a hotspot region and lead us 
to begin the characterization of the R925H mutation.  
R925H mutant vinculin had lower actin bundling ability. 
 As the R925H mutation was confirmed as a hotspot region, we thought it was important 
to investigate how this mutation would affect the binding and bundling activity of vinculin 
(Figure 2).  Since the R925H mutation occurred in the vinculin tail domain, a region important in 
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the process of both binding and bundling actin, we hypothesized that vinculin’s ability to bind 
and bundle actin would be compromised. We conducted high-speed actin co-sedimentation 
assays to test the binding ability of wild-type vinculin, R925H mutant vinculin and wild-type 
metavinculin. To test the bundling activity for these three proteins, we conducted low-speed 
actin co-sedimentation assays. Quantification of the SDS-PAGE analysis of these assays 
revealed differences among the three proteins in their actin bundling activity. Mutant vinculin 
exhibited lower actin bundling activity than wild-type vinculin, and this difference was 
determined to be significantly different (p < 0.01) (Figures 2C and 2D). This demonstrated that 
the R925H mutant vinculin had lower actin bundling activity. However, the difference of actin 
bundling activity between mutant vinculin and wild-type vinculin was not statistically 
different—signifying that bundling activities of both proteins were similar (Figures 2A and 2B). 
Therefore, we concluded that the R925H mutation in vinculin caused a decrease in actin 
bundling activity as compared to wild-type vinculin.  
Elongated focal adhesions and rounded cell morphology observed in R925H mutant MEFs, 
which express the same levels of vinculin as wild-type MEFs. 
Since the R925H mutant vinculin demonstrated lower bundling activity, we further 
studied how this mutation would manifest in cellular phenotype (Figure 2). We hypothesized that 
R925H mutant MEFs would demonstrate visual differences in focal adhesions and cell 
morphology as compared to wild-type MEFs. We chose the MEF model cell line for this 
experiment because vinculin knockout MEFs have been well characterized in previous 
studies.6,9,11 MEFs facilitated a clear comparison between the motility results of null, wild-type 
and mutant cells. All MEFs were sorted by flow cytometry and quantified by a western blot 
(Figure 3A, Supplemental Figure 2). Endogenous vinculin expression in both R925H mutant 
MEFs and wild-type MEFs were determined to be equal (Figure 3A). Vinculin null MEFs 
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demonstrated little to no vinculin expression. The random motility assays were only conducted 
with MEFs that expressed high levels of wild-type and mutant vinculin (Supplemental Figure 2). 
To visualize the differences between mutant, wild-type and null MEFs, fluorescence microscopy 
images were taken of all three cell types (Figure 3B). Endogenous vinculin tagged with 
mEmerald fluorophores allowed us to observe the focal adhesions in mutant and wild-type 
MEFs. Paxillin staining was used to visualize focal adhesions in vinculin null MEFs. R925H 
mutant MEFs demonstrated larger, elongated focal adhesions. Moreover, mutant MEFs showed a 
more compact, rounded cell morphology. Whereas, wild-type MEFs demonstrated larger cell 
shape and smaller focal adhesions. Vinculin null MEFs were completely circular in shape and 
had the smallest focal adhesions, which corroborated previous characterization of cell 
morphology of vinculin null MEFs (Figure 3B).6 In sum, the R925H mutation induced elongated 
focal adhesions and rounded cell morphology in MEFs.  
R925H mutant MEFs had a higher average velocity on mid-stiffness hydrogel as compared to 
wild-type MEFs.  
After studying differences in focal adhesions, we next tested whether specific aspects of 
migration were affected by the mutation. We hypothesized that the R925H mutant MEFs would 
demonstrate a higher velocity than wild-type MEFs. To measure the velocity of all three cell 
types on both hydrogels and glass, individual cell tracks from the random migration assays were 
manually tracked and velocity values for each cell were generated using the chemotaxis tool on 
ImageJ (Figure 4A). It is important to note that the average velocity value for wild-type MEFs 
was used as the standard to which the other cell types were compared to in a multiple-
comparisons ANOVA test (95% CI). For the MEFs tracked on mid-stiffness hydrogels, R925H 
mutant cells showed a higher average velocity than both wild-type and null cells. The R925H 
mutant, wild-type, and null MEFs had average velocities of 1.36 μm/min, 1.09 μm/min, and 0.87 
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μm/min, respectively, on hydrogels. The average velocity of mutant MEFs was found to be 
statistically greater than the average velocity of wild-type MEFs (p < 0.01). Vinculin null MEFs 
demonstrated a significantly lower average velocity than that of wild-type MEFs (p < 0.05) 
(Figure 4B). On the other hand, contrasting results were observed on glass surface—R925H 
mutant, wild-type, and null MEFs had average velocities of 0.35 μm/min, 0.40 μm/min, and 0.41 
μm/min, respectively on glass. The R925H mutant MEFs demonstrated the lowest velocity out of 
all three cell types. The difference in velocity between wild-type and mutant MEFs was deemed 
to not be statistically significant—the same was observed for the difference in velocity between 
wild-type and vinculin null MEFs (Figure 4C). Overall, this data demonstrated that the R925H 
mutant MEFs demonstrated a higher velocity than wild-type and vinculin null MEFs on the mid-
stiffness hydrogel. 
Notably, the average velocity of vinculin null MEFs was not determined to be statistically 
different from wild-type and mutant MEFs. This data is inconsistent with previous data that 
reports that vinculin null cells statistically demonstrate the highest velocity on glass.6,9 The 
variance between our data and literature values could be attributed to the difference between 
experimental conditions utilized for motility assays conducted on glass. Differences include 
incubation period, magnification, tracking time interval, and the number of cells analyzed.6 Due 
to this contradiction, we cannot conclude that mutant MEFs have a higher velocity than wild-
type or null MEFs. Rather, we conclude that the R925H mutation causes a possible difference in 
velocity. To elucidate precise differences in velocity caused by this mutation, further 





R925H mutant MEFs had a lower average persistence on mid-stiffness hydrogel as compared 
to wild-type MEFs. 
To study other specific aspects of migration that were affected by the R925H mutation, 
we also explored the differences in persistence observed across the three cell types on both mid-
stiffness hydrogels and glass. Persistence is defined as the tendency of the cell to move in one 
particular direction. We hypothesized that R925H mutant MEFs would demonstrate less 
persistence than wild-type MEFs. The values of persistence for each type of MEF were obtained 
in the same manner as the velocity values were. Average persistence values were compared 
using multiple-comparisons ANOVA tests (95% CI). On hydrogels, R925H mutant, wild-type 
and null MEFs demonstrated average persistence values of 0.28 μm/min, 0.34 μm/min, and 0.26 
μm/min, respectively. The average persistence of mutant R925H and wild-type MEFs were 
determined to be statistically different (p < 0.05). Additionally, the wild-type MEFs 
demonstrated a significantly higher average persistence than that of vinculin null MEFs (p < 
0.001). Average persistence values calculated from random motility done on glass exhibited a 
similar trend to those done on hydrogels. R925H mutant, wild-type, and null MEFs had average 
persistence values of 0.38 μm/min, 0.42 μm/min, and 0.32 μm/min, respectively on glass. 
However, the average persistence of null and mutant MEFs were not deemed to be statistically 
different from that of wild-type MEFs. All of these data demonstrated that R925H mutant MEFs 
demonstrated a significantly lower average persistence on mid-stiffness hydrogels. However, we 
cannot conclude that mutant MEFs have lower persistence than wild-type MEFs because of the 
insignificant differences observed in persistence values of MEFs analyzed on glass. From this 
data, we conclude that the R925H mutation causes a possible difference in persistence. Precise 




R925H mutant MEFs have a higher average accumulated distance on mid-stiffness hydrogel 
as compared to wild-type MEFs.  
The last aspect of migration that we analyzed was accumulated distance, which is defined 
as the total amount of distance a cell travels. Just as velocity and persistence, accumulated 
distance was measured in all three cell types, observed on both hydrogels and glass, and 
compared with a multiple-comparisons ANOVA test (95% CI). We hypothesized that mutant 
MEFs would demonstrate greater accumulated distance than both null and wild-type cells. 
Average accumulated distance on hydrogels for mutant, wild-type, and null MEFs were 
determined to be 580.86 μm, 383.11 μm, and 461.40 μm, respectively. The average accumulated 
distance of R925H mutant MEFs was determined to be significantly higher than that of wild-type 
cells (p < 0.001). However, the difference between the average accumulated distance between 
wild-type and null MEFs was not deemed to be statistically different. This trend was not 
observed on glass—R925H mutant, wild-type, and null MEFs had average accumulated 
distances of 203.00 μm, 239.64 μm, and 218.74 μm, respectively. These values indicate that the 
R925H MEFs traveled the least amount of total distance out of the three cell types. Further, the 
average accumulated distance of null and mutant MEFs were not statistically different from that 
of wild-type MEFs. Overall, these data demonstrated that R925H mutant MEFs had a 
significantly higher average accumulated distance on mid-stiffness hydrogels. However, 
accumulated distance of MEFs studied on glass was determined to not be statistically different 
among the three cell types. Similarly, to velocity and persistence, further investigation is required 
to draw precise conclusions regarding accumulated distance. From the data we gathered, we can 






         Our original hypothesis was that the R925 residue would be a hotspot region and that 
MEFs expressing the R925H mutation would induce cell morphology similar to those of cancer 
cells. Further, we speculated that MEFs expressing this mutation would demonstrate actin 
bundling deficiencies and show differences in cell motility—specifically, higher velocity, lower 
persistence and greater accumulated distance. These properties would be similar to the motility 
traits demonstrated by vinculin null MEFs.6,9,11,12 
The R925H mutation in the tail domain of vinculin was associated with 12 reported cases 
of cancer, the greatest number of cases involved with one mutation out of the 33 mutations found 
in cancer databases. This prominent mutation was linked to esophageal, uterine, lung, cervical, 
and stomach cancers. Our collected data demonstrates that the R925H mutation has a higher 
propensity to mutate and manifest cancer phenotypes relative to other regions in vinculin. 
Therefore, R925H was confirmed to occur in a hotspot region. Further, the importance of the 
R925 residue is emphasized by the critical role it plays in the vinculin tail domain for both actin 
reorganization and lipid interactions. Our data demonstrates that the R925H mutant vinculin 
shows lower actin bundling activity. Additionally, this hotspot mutation was observed to cause 
some differences in the phenotype. Notably, mutant MEFs displayed elongated and more 
numerous focal adhesions than wild-type MEFs. Mutant MEFs also demonstrated more rounded 
and compact morphology than the other two cell types.  
Random motility assays aimed to differentiate between the motility of MEFs with the 
R925H mutant MEFs, wild-type MEFs, and vinculin null MEFs. Random motility assays 
showed that there were insignificant differences between the velocity, persistence, and 
accumulated distance of wild-type MEFs and mutant MEFs. The MEF cells on mid-stiffness 
hydrogels, however, demonstrated significant differences between the mutated and wild-type 
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cells. The mutant MEFs expressed greater velocity, higher accumulated distance, and lower 
persistence. The differences observed in trends of migratory parameters observed on glass and 
mid-stiffness hydrogels, along with the data that demonstrated the phenotypic tendencies of 
MEFs expressing mutant vinculin, allowed us to conclude that the R925H mutant causes changes 
in motility. Further investigation is required to draw exact interpretations of what aspects of 
motility are affected in cells expressing the R925H mutation.  
R925H mutant vinculin was actin bundling deficient, which correlated to the extensively-
characterized LD-CT (vinculin R1060Q/K1061Q) vinculin variant.14 This variant retained actin 
binding but showed significant deficiency in F-actin crosslinking, otherwise known as actin 
bundling. This study concluded that the decrease in actin-bundling was not due to a decrease in 
the ability of MEFs to respond to external forces, but rather due to a disruption of the ability of 
vinculin to crosslink actin. Further, this study emphasized that the role of vinculin in 
mechanotransduction and cell stiffness is primarily driven by actin binding and crosslinking. 14 
Paralleling this study, the R925H mutation is also perceived to cause a disruption of the ability of 
vinculin to crosslink actin. This could affect actin assembly and disassembly at focal adhesions 
during the migration of the cell.  
 Nascent focal adhesions are thought to have rapid vinculin activation and turnover, 
causing faster actin assembly and disassembly. Related to having faster velocity, cells that turn 
over their focal adhesions quickly can display phenotypes related to a loss of a tumor suppressor, 
such as promoting metastasis of cancer cells. 14 Focal adhesions in vinculin null cells resemble 
nascent focal adhesions described.6,11,12 This led us to predict that the motility of vinculin null 
cells was representative of the motility of cancer cells. Since the R925H mutation was linked to 
several types of cancer, we originally postulated that the mutant cells would also demonstrate 
migratory properties similar to that of vinculin null cells and cancer cells.  
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However, the motility of the MEF cells studied on glass contradicted the results 
published in previous literature.6,9 The R925H mutation is suspected to compromise the 
functions of vinculin, which in theory would lead to these mutant cells expressing phenotypes 
similar to those of vinculin null cells—these phenotypic properties are correlated with cancer 
like metastasis in MEF cells.11,12 These traits of cell motility involve a higher velocity, less 
persistence and a greater accumulated distance. However, our results pertaining to glass did not 
provide significant differences between the velocity, persistence, or accumulated distance. This 
is of concern because previous literature has claimed that vinculin null cells migrating on glass 
should exhibit higher speed motility and more migration on glass compared to the wild-type 
cells, according to previously published studies.6,9  
The variance among results can partly be attributed to the difference between the 
experimental conditions used for each of the random motility assays conducted on glass. 
Previous studies utilized a 24-hour incubation period after plating the cells, while our 
experiments used a 2-hour incubation period.6 Further, the previous studies implemented a 10x 
magnification and a 10-hour tracking time interval.6 We utilized 20x magnification and a 20-hour 
tracking time interval. These distinctions in data collection factors could be responsible for the 
differences observed in the results. Moreover, the number of cells tracked on glass in this 
experiment was substantially less than the number of cells studied in previous literature.6 A 
greater population of cells in each group allowed previous studies to draw statistically significant 
conclusions. Additionally, since the values for both wild-type and mutant cells for each 
parameter were very similar, it can be considered that the mutation made little to no difference in 
the cells’ motility—which further negates our original hypothesis. 
 We expected mutant MEFs studied on mid-stiffness hydrogels to demonstrate similar 
motility to the vinculin null cells studied in previous literature as well.6,9 MEFs studied on 
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hydrogels corroborated our hypothesis because R925H mutants exhibited higher velocity, lower 
persistence, and more accumulated distance than the wild-type MEFs. These properties of 
motility could have been induced by the greater mechanical stimulus placed on the MEFs by the 
mid-stiffness hydrogels. Since greater mechanical stimulus causes migrating cells to have cell 
membranes with increased stiffness, mid-stiffness hydrogels mimic physiological conditions of 
cancer cells. This is not taken into account when studying motility on glass.6 However, there 
were slight inconsistencies with the vinculin null MEFs on the hydrogels.  
One inconsistency observed in the random motility assay conducted on hydrogels was 
that the difference between average accumulated distance of wild-type and null MEFs was 
deemed statistically insignificant. Though the mutant cell group demonstrated more accumulated 
distance than that of the wild-type cells, the null cells did not display an equally high 
accumulated distance. Additionally, vinculin null MEFs did not demonstrate the expected similar 
velocity or persistence as those of R925H mutant MEFs. Though further research needs to be 
conducted on this aspect of MEF cell motility, we conjecture that these inconsistencies could be 
attributed to cells lacking vinculin and consequently the loss of the scaffold when exposed to the 
mechanical force of the mid-stiffness hydrogel.  
A possible error that could have contributed to the difference between the random 
motility results of previous literature and those of this experiment on glass is that the media used 
to grow the cells could have been contaminated. This could affect the morphology of the cells 
and their ability to grow. Specifically, for the random motility assays conducted on glass, a small 
amount of debris was observed in the media in a portion of the frames when selecting positions 
for tracking migration pathways. This could affect the migratory pathways of the cells, which in 
turn would have affected our results. An improvement that could be made to this experiment is to 
strengthen the criteria that each cell needs to meet in order to be tracked. In this study, cells were 
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tracked as long as they stayed within the frame and up until they divided. Perhaps, it is 
worthwhile to only track cells that do not leave the frame at all in the 60-minute time period and 
exclude cells that divide from the data. This will rid the experiment of some extraneous factors 
that could affect the motility of the cells.  
Outside of these inconsistencies, it could be extrapolated that there are significantly 
different cell motility patterns observed between R925H mutants and wild-type MEFs. The 
R925H mutation does cause a difference in cell motility, though further investigation is required 
to analyze which aspects of motility are affected. Future directions involving the characterization 
of the R925H mutation involve repeating random motility assays on mid-stiffness hydrogels with 
more cells (n>200 per cell type). In addition, we will study motility on low-stiffness and high-
stiffness hydrogels. We will also categorize and quantify the focal adhesions in mutant cells. 
Furthermore, morphological changes induced by this mutation in the cell could be more closely 
observed, including the effects of the R925H mutation on vinculin’s interactions with other 
proteins. Cell proliferation assays will also be conducted to understand how this mutation affects 
cell division. Lastly, we could examine the possibility of the R925H mutation upregulating and 
downregulating other missense mutations in vinculin itself. However, the primary insights on the 
effects of the R925H mutation on cell motility described by this project will serve as one of the 
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Database Number of Cases 
Reported 
Type of Cancer Type of Mutation (Base Change) Vinculin Position 
cBio Portal 7 Esophageal, Uterine, 
Lung, Cervical 
Missense R925H 
cBio Portal 3 Stomach, Cutaneous Missense R945W/R945L 
cBio Portal 3 Cutaneous, Thyroid, 
Colorectal 
Missense R976L/R976Q 
cBio Portal 2 Prostate Missense R1039W 
cBio Portal 3 Uveal, Angiosarcoma, 
Brain 
Missense R785 
cBio Portal 3 Colorectal, Pancreatic Missense D742N/E 
cBio Portal 5 Breast, Colorectal, 
Skin Cutaneous 
Missense R712H/C/S 
cBio Portal 3 Uterine, Cervical, 
Pancreatic 
Missense R694Q 
COSMIC 2 Breast Missense I1046T 
COSMIC 2 Hematopoietic and 
Lymphoid 
Missense A1003T 
COSMIC 2 Hematopoietic and 
Lymphoid 
Missense L899V 
intOGen 1 N/A Synonymous variant AA947 
intOGen 1 N/A Missense AA963 
intOGen 1 N/A Missense AA1008 
intOGen 1 N/A Missense AA1017 
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intOGen 1 N/A Synonymous variant AA1033 
intOGen 1 N/A Missense AA1044 
intOGen 1 N/A Missense AA1054 
GDC 5 Esophagus, Stomach, 
Uterus, Cervix, Lung 
Missense R925H 
GDC 2 Colon, Rectum Missense R1049Q 
GDC 2 Corpus Uteri, Uterus Missense D880N 
GDC 2 Colon, Rectosigmoid 
junction 
Missense A901V 
GDC 2 Corpus Uteri, Uterus Missense D788Y 
OASIS 1 Colon Missense K779R 
OASIS 1 Colon Missense A833V 
OASIS 1 Gastric Missense A887T 
OASIS 1 Head-Neck Missense S944T 
OASIS 1 Head-Neck Missense A976V 
OASIS 1 Lung Missense R895L 
OASIS 1 Ovarian Missense T941N 
OASIS 1 Rectal Missense R981Q 
OASIS 1 Uterine Missense R940 
Supplemental Figure 1.  Data mining procedure demonstrates that R925 is a hotspot region. 
Databases used to compile this data: cBIO Portal, Catalogue of Somatic Mutations in Cancer 
(COSMIC), Integrative Oncogenomics (intOGen), Genomic Data Commons Data Portal (GDC), 






























Supplemental Figure 2. mEmerald vinculin and mEmerald R925H mutant vinculin were 
sorted for expression level using flow cytometry. Dr. Mohammad Ashhar Khan performed flow 
cytometry and generated all cell sorting plots in this figure. For all panels, gate R3 represents the 
proportion of MEFs that had a ‘medium’ level of vinculin expression and R4 represents the 
proportion of MEFs that had a ‘high’ level of vinculin expression. (A) Sort data for mEmerald 
vinculin in vinculin null MEFs. Vinculin null MEFs with the no expression of vinculin were 
chosen for random motility assays. (B) Sort data for mEmerald vinculin in wild-type vinculin 
MEFs. Wild-type MEFs with high expression of vinculin were chosen for random motility 
assays. (C) Sort data for mEmerald R925H mutant vinculin in wild-type vinculin MEFs. Mutant 
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